Coronary Artery Disease Clinical Trial
— Val-CARDOfficial title:
A Randomised Controlled Trial of Pre-surgery Sodium ValpRoate, for the Prevention of Organ Injury in Cardiac Surgery: THE Val-CARD TRIAL
The Val-CARD trial aims to answer the question: "Does the drug sodium valproate reduce complications affecting the heart and kidneys in patients having heart operations?" Sodium valproate is a drug commonly used in the treatment of epilepsy. Recently it has been shown to protect against heart and kidney damage in laboratory tests. This has led to trials evaluating whether it can prevent heart and kidney damage in patients. The investigators wish to evaluate whether treatment with sodium valproate for a short period can reduce levels of organ damage following heart surgery by measuring this in blood tests, exercise tests, a special x-ray measuring body fat content, a walk exercise and muscle strength tests. The investigators now want to establish if sodium valproate works by making the heart and kidney more resistant to any injury that results from the use of the heart lung machine.
Status | Recruiting |
Enrollment | 122 |
Est. completion date | October 7, 2024 |
Est. primary completion date | October 7, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult cardiac surgery patients (=18 years) undergoing cardiac surgery (CABG, Valve, or CABG and Valve) with cardiopulmonary bypass (CPB). - Able, in the opinion of the investigator, and willing to give informed consent. Exclusion Criteria: - Emergency or salvage procedure - Patients with end stage renal failure defined as an estimated Glomerular Filtration rate (eGFR) <15 mL/min/1.72 m2 calculated from the Modification of Diet in Renal Disease equation,1 or patients who are on long-term haemodialysis or have undergone renal transplantation. - Patients with persistent or chronic atrial fibrillation. - Patients with acute liver disease. - Personal or family history of severe hepatic dysfunction, especially drug related. - Patients allergic to sodium valproate. - Patients with thrombocytopaenia (platelet count <150x109 per mL). - Patients taking long-term Histone Deacetylase Inhibitors such as sodium valproate. - Patients taking any of the following medications: antipsychotics, MAO inhibitors, antidepressants and benzodiazepines, Lithium, Olanzepine, Phenobarbital, Primidone, Phenytoin, Carbamazepine, Lamotrigine, Felbamate. - Patients diagnosed with a mitochondrial deficiency disorder. - Patients with porphyria. - Patients with known urea cycle disorders. - Women of child bearing potential (WOCBP) are excluded from the study. A woman is defined as being of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal, unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. - Patients who are participating in another interventional clinical trial. - Unable, in the opinion of the investigator, or unwilling to give informed consent protocol. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Glenfield Hospital | Leicester | Leicestershire |
Lead Sponsor | Collaborator |
---|---|
University of Leicester |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of Serum Creatinine level | Measurement of serum creatinine level and expressed as umol/L. | Baseline, 2 weeks, 4 weeks, 0-6, 6-12, 24, 48, 72, and 96 hours post-operatively | |
Primary | Change of Serum Troponin I level | Measurement of serum Troponin level and expressed as ng/L. | Baseline, at 0-6, 6-12, 24, 48 and 72 hours post-operatively | |
Secondary | Change in Multiple organ dysfunction - Sepsis-related Organ Failure Assessment (SOFA) Score) | Range 0-3, 3 being the worse score | Baseline, 4 weeks, 0-6, 24, 48, 72 and 96 hours | |
Secondary | NGAL (Neutrophil gelatinase associated lipocalcin) | Measurement of NGAL level and expressed as µg/L. | Baseline, day before surgery, 6-12, 24 and 48 hours post-surgery. | |
Secondary | Lung Injury - Arterial alveolar oxygen (PaO2/FiO2) ratios | Measurement of PaO2/FiO2 ratio and expressed in kPa/L. | Baseline, day before surgery, 24, 48, 72 and 96 hours post-surgery. | |
Secondary | AST (Aspartate Transaminase) | Measurement of AST levels in serum and expressed in IU/L. Acute liver injury will be defined as an acute derangement of three times the upper limit of normal. | Baseline, day before surgery, 0-6, 6-12, 24, 48, 72 and 96 hours post-surgery | |
Secondary | ALT (Alanine Transaminase) | Measurement of ALT levels in serum and expressed in IU/L. Acute liver injury will be defined as an acute derangement of three times the upper limit of normal. | Baseline, day before surgery, 0-6, 6-12, 24, 48, 72 and 96 hours post-surgery | |
Secondary | Bilirubin | Measurement of Bilirubin levels in serum and expressed in µmol/L. Acute liver injury will be defined as an acute derangement of three times the upper limit of normal. | Baseline, day before surgery, 0-6, 6-12, 24, 48, 72 and 96 hours post-surgery | |
Secondary | Alkaline Phosphatase | Measurement of Alkaline Phosphatase levels in serum and expressed in IU/L. Acute liver injury will be defined as an acute derangement of three times the upper limit of normal. | Baseline, day before surgery, 0-6, 6-12, 24, 48, 72 and 96 hours post-surgery | |
Secondary | Serum Amylase | Measurement of Amylase levels in serum and expressed in IU/L. Acute pancreatitis will be defined as a serum amylase concentration >1000 ng/ml. | Baseline, day before surgery, 0-6, 6-12, 24, 48, 72 and 96 hours post-surgery | |
Secondary | Assessment of resource use - Time until extubation | Time (hours) measured from the start of surgery - to extubation (up to 30 days) | ||
Secondary | Length of stay in Intensive Care Unit | Number of hours between admission and discharge from the Intensive Care Unit (ICU). | Time (hours) measured from the start of surgery to discharge from ICU (up to 30 days) | |
Secondary | Length of Stay in Hospital | Number of days between the date of surgery and discharge from the hospital. | Time (days) measured from the start of surgery to discharge from hospital (up to 90 days) | |
Secondary | Sepsis | Sepsis is defined as: Suspected or documented infection and an acute change in total Sepsis-related Organ Failure Assessment (SOFA) score =2 points consequent to the infection. Range of SOFA is 0 to 3, 3 being the worse score. | Baseline, 4 weeks before surgery, 0-6, 6-12, 24, 48, 72 and 96 hours post-surgery | |
Secondary | Rate of mortality | Rate of mortality at 30-day and 1 year from the date of surgery. | Within 30-days from surgery and at 1 year from surgery | |
Secondary | Bleeding and Transfusion | The total number of units of red cells and other blood components transfused during the operative period and post-operative hospital stay | Intra-operative and between time of surgery and hospital discharge up to two weeks | |
Secondary | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | Adverse events as assessed for type and severity by CTCAE v4.0 | Post-operative up to 3 months follow-up from time of surgery | |
Secondary | Mechanism study: Mithocondrial function of microvessels from tissue biopsies | 50-100 mg biopsies obtained from pedicled left internal mammary artery biopsies. The mitochondrial function will be measured through the Bioenergetic Health Index. The Bioenergetic Health Index (BHI) is calculated using the following formula: BHI=(ATP-linked×reserve capacity)/(proton leak×non-mitochondrial) - as described by Chacko et al. The expected range is 0-100. | At time of surgery | |
Secondary | Mechanism study: microRNAs isolation from microvessels | The findings will be represented by the frequency (%) of identified microRNAs. 50-100 mg biopsies obtained from pedicled left internal mammary artery biopsies. | At time of surgery | |
Secondary | Mechanism study: Chromatin Immunoprecipitation (ChIP) of microvessels from tissue biopsies | To identify protein binding sites that may help identify functional elements in the genome.
Findings will be represented by the number (n) of binding sites. 50-100 mg biopsies obtained from pedicled left internal mammary artery biopsies. |
At time of surgery | |
Secondary | Mechanism study: Mithocondrial function measured in right atrium myocardium tissue biopsies | 50-100 mg myocardial biopsies will be obtained from the right atrium at surgery. The mitochondrial function will be measured through the Bioenergetic Health Index. The Bioenergetic Health Index (BHI) is calculated using the following formula: BHI=(ATP-linked×reserve capacity)/(proton leak×non-mitochondrial) - as described by Chacko et al. The expected range is 0-100. | At time of surgery | |
Secondary | Mechanism study: microRNA isolation from right atrium myocardium tissue biopsies | 50-100 mg myocardial biopsies will be obtained from the right atrium at surgery. The findings will be represented by the frequency (%) of identified microRNAs. | At time of surgery | |
Secondary | Mechanism study: Chromatin Immunoprecipitation (ChIP) in right atrium myocardium tissue biopsies | 50-100 mg myocardial biopsies will be obtained from the right atrium at surgery. To identify protein binding sites that may help identify functional elements in the genome.
Findings will be represented by the number (n) of binding sites. |
At time of surgery | |
Secondary | Mechanism study: Mithocondrial function measured in adipose tissue biopsies | Adipose tissue collected from epicardial fat at time of surgery. The mitochondrial function will be measured through the Bioenergetic Health Index. The Bioenergetic Health Index (BHI) is calculated using the following formula: BHI=(ATP-linked×reserve capacity)/(proton leak×non-mitochondrial) - as described by Chacko et al. The expected range is 0-100. | At time of surgery | |
Secondary | Mechanism study: microRNA isolation in adipose tissue biopsies | Adipose tissue collected from epicardial fat at time of surgery. The findings will be represented by the frequency (%) of identified microRNAs. | At time of surgery | |
Secondary | Mechanism study: Chromatin Immunoprecipitation (ChIP) in adipose tissue biopsies | Adipose tissue collected from epicardial fat at time of surgery. To identify protein binding sites that may help identify functional elements in the genome.
Findings will be represented by the number (n) of binding sites. |
At time of surgery | |
Secondary | Mechanism study: Measurement of microvesicles in urine samples | Identification of microvesicles. The findings will be represented by the frequency (%) of each identified microvesicle. | 1 day before surgery, 12 and 24 hours following surgery | |
Secondary | Mechanism study: Measurement of microRNAs in urine samples | The findings will be represented by the frequency (%) of identified microRNAs. | 1 day before surgery, 12 and 24 hours following surgery | |
Secondary | Mechanism study: Measurement of histone acetylation in urine samples | The findings will be reported as acetylated H3 (ug/mg) over time (hours) | 1 day before surgery, 12 and 24 hours following surgery | |
Secondary | Mechanism study: Measurement of gene expression in urine samples | Whole genome sequencing will be achieved through ATAC sequencing. The identified genes will be characterised by average expression count over ATAC. | 1 day before surgery, 12 and 24 hours following surgery | |
Secondary | Mechanism study: Cardiac Magnetic Resonance Imaging - Cardiac Function | Assessment of cardiac function, by assessing ventricular function. This will be expressed as ejection fraction (%). Intravenous contrast will be administered via an indwelling venous catheter. | Baseline, 1 day before surgery and 3 months following surgery | |
Secondary | Mechanism study: Cardiac Magnetic Resonance Imaging - Cardiac adiposity content | Assessment of cardiac adiposity content. A percentage of adipose tissue over total body mass will be calculated. Intravenous contrast will be administered via an indwelling venous catheter. | Baseline, 1 day before surgery and 3 months following surgery | |
Secondary | Mechanism study: Cardiac Magnetic Resonance Imaging - Visceral adiposity content | Assessment of visceral adiposity content. A percentage of adipose tissue over total body mass will be calculated. Intravenous contrast will be administered via an indwelling venous catheter. | Baseline, 1 day before surgery and 3 months following surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |